These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

168 related items for PubMed ID: 2174966

  • 1. In vitro and in vivo antitumor properties of a T-cell clone generated from murine tumor-infiltrating lymphocytes.
    Fox BA, Spiess PJ, Kasid A, Puri R, Mulé JJ, Weber JS, Rosenberg SA.
    J Biol Response Mod; 1990 Oct; 9(5):499-511. PubMed ID: 2174966
    [Abstract] [Full Text] [Related]

  • 2. Enhanced cytolytic activity of tumor infiltrating lymphocytes (TILs) derived from an ICAM-1 transfected tumor in a murine model.
    Lefor AT, Fabian DF.
    J Surg Res; 1998 Feb 15; 75(1):49-53. PubMed ID: 9614856
    [Abstract] [Full Text] [Related]

  • 3. Human tumor antigen-specific T lymphocytes and interleukin-2-activated natural killer cells: comparisons of antitumor effects in vitro and in vivo.
    Whiteside TL, Sung MW, Nagashima S, Chikamatsu K, Okada K, Vujanovic NL.
    Clin Cancer Res; 1998 May 15; 4(5):1135-45. PubMed ID: 9607570
    [Abstract] [Full Text] [Related]

  • 4. Enhanced cell-mediated cytotoxicity by interferon-gamma and interleukin-2 against syngeneic murine mammary adenocarcinoma.
    Nakajima I, Chu TM.
    Mol Biother; 1992 Mar 15; 4(1):47-52. PubMed ID: 1627274
    [Abstract] [Full Text] [Related]

  • 5. Modulation of murine tumor major histocompatibility antigens by cytokines in vivo and in vitro.
    Weber JS, Rosenberg SA.
    Cancer Res; 1988 Oct 15; 48(20):5818-24. PubMed ID: 3139284
    [Abstract] [Full Text] [Related]

  • 6. Characteristics and in vivo homing of long-term T-cell lines and clones derived from tumor-draining lymph nodes.
    Matsumura T, Sussman JJ, Krinock RA, Chang AE, Shu S.
    Cancer Res; 1994 May 15; 54(10):2744-50. PubMed ID: 8168105
    [Abstract] [Full Text] [Related]

  • 7. Augmenting major histocompatibility complex class I expression by murine tumors in vivo enhances antitumor immunity induced by an active immunotherapy strategy.
    Merritt RE, Yamada RE, Crystal RG, Korst RJ.
    J Thorac Cardiovasc Surg; 2004 Feb 15; 127(2):355-64. PubMed ID: 14762342
    [Abstract] [Full Text] [Related]

  • 8. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
    Freedman RS, Kudelka AP, Kavanagh JJ, Verschraegen C, Edwards CL, Nash M, Levy L, Atkinson EN, Zhang HZ, Melichar B, Patenia R, Templin S, Scott W, Platsoucas CD.
    Clin Cancer Res; 2000 Jun 15; 6(6):2268-78. PubMed ID: 10873077
    [Abstract] [Full Text] [Related]

  • 9. Antitumor effects of alpha-interferon and gamma-interferon on a murine renal cancer (Renca) in vitro and in vivo.
    Sayers TJ, Wiltrout TA, McCormick K, Husted C, Wiltrout RH.
    Cancer Res; 1990 Sep 01; 50(17):5414-20. PubMed ID: 2117482
    [Abstract] [Full Text] [Related]

  • 10. Skewing the Th cell phenotype toward Th1 alters the maturation of tumor-infiltrating mononuclear phagocytes.
    Nonaka K, Saio M, Suwa T, Frey AB, Umemura N, Imai H, Ouyang GF, Osada S, Balazs M, Adany R, Kawaguchi Y, Yoshida K, Takami T.
    J Leukoc Biol; 2008 Sep 01; 84(3):679-88. PubMed ID: 18566103
    [Abstract] [Full Text] [Related]

  • 11. Antitumor effect of interleukin (IL)-12 in the absence of endogenous IFN-gamma: a role for intrinsic tumor immunogenicity and IL-15.
    Gri G, Chiodoni C, Gallo E, Stoppacciaro A, Liew FY, Colombo MP.
    Cancer Res; 2002 Aug 01; 62(15):4390-7. PubMed ID: 12154045
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Immunoselection of a human melanoma resistant to specific lysis by autologous tumor-infiltrating lymphocytes. Possible mechanisms for immunotherapeutic failures.
    Topalian SL, Kasid A, Rosenberg SA.
    J Immunol; 1990 Jun 01; 144(11):4487-95. PubMed ID: 2160503
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes.
    Hwu P, Yang JC, Cowherd R, Treisman J, Shafer GE, Eshhar Z, Rosenberg SA.
    Cancer Res; 1995 Aug 01; 55(15):3369-73. PubMed ID: 7614473
    [Abstract] [Full Text] [Related]

  • 18. In vitro enhanced cytotoxicity of tumor-infiltrating lymphocytes transfected with tumor necrosis factor-related apoptosis-inducing ligand and/or interleukin-2 gene in human renal cell carcinoma.
    Tian JQ, Wang ZP, Rodriguez R, Fu JS, Lu JZ, Ma BL.
    Urology; 2006 May 01; 67(5):1093-8. PubMed ID: 16635513
    [Abstract] [Full Text] [Related]

  • 19. Successful adoptive cellular immunotherapy is dependent on induction of a host immune response triggered by cytokine (IFN-gamma and granulocyte/macrophage colony-stimulating factor) producing donor tumor-infiltrating lymphocytes.
    Nagoshi M, Goedegebuure PS, Burger UL, Sadanaga N, Chang MP, Eberlein TJ.
    J Immunol; 1998 Jan 01; 160(1):334-44. PubMed ID: 9551989
    [Abstract] [Full Text] [Related]

  • 20. Synergistic actions of picibanil (OK-432) on recombinant interleukin-2 induction of tumor-infiltrating lymphocyte expansion, cytotoxicity, and phenotypic differentiation.
    Lafreniere R, Borkenhagen K, Bryant LD, Ng E, Hayton S.
    J Biol Response Mod; 1990 Feb 01; 9(1):53-60. PubMed ID: 2181072
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.